Israeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat congenital emphysema.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments